This policy report examines the push and pull factors that contribute to the formation of so-called “migrant caravans” and offers policy recommendations to staunch the flow of migrants through Mexico.
In this report, the authors outline the U.S. federal budget process for scientific R&D, discuss trends in federal R&D funding and provide an outlook for federal scientific R&D funding during the Biden administration.
The director of the White House Office of Science and Technology Policy (OSTP) plays a central role in advising the president on the impact of science and technology on domestic and global affairs, and on federal funding of scientific research. This paper provides recommendations for the next president to consider when choosing a science advisor and establishing science and technology policy priorities. The project also offers guidance to the next science advisor for developing effective policy while serving in the White House. The recommendations are based on lessons learned from past presidential science advisors as well as feedback from more than 60 reviewers, including individuals who currently serve or have served the OSTP, the President’s Council of Advisors for Science and Technology, federal agencies, Congress or congressional staff, and nongovernmental organizations as well as policy scholars.
Neal F. Lane, Kirstin R.W. Matthews, Kenneth M. EvansSeptember 12, 2016
State "right to try" laws can give terminally ill patients early access to experimental drugs and medical devices — but they arguably make safety and efficacy secondary to speedy access.
Baker Institute Policy Report #64 highlights some of the central ethical issues pertaining to NTD policy development and argues that ethical considerations should be included in the policy development process.
Kirstin R.W. Matthews, Ana S. IltisFebruary 29, 2016
Baker Institute Policy Report #65 summarizes the key findings of the Baker Institute conference "The United States and Mexico: Addressing a Shared Legacy of Neglected Tropical Diseases and Poverty."
Jennifer R. Herricks, Kirstin R.W. Matthews, Peter J. HotezFebruary 15, 2016
This report describes the problems associated with unproven stem cell treatments, focusing on those without FDA approval undertaken by NFL players in the past five years.
Stem cells from umbilical cord blood (CB) can be used to treat over 80 different diseases, including many types of leukemia, lymphoma and inherited immune system disorders. Extensive storage facilities in the United States and around the world collect, test and freeze CB for later use in medical procedures. However, the divide between two different banking models — public versus private — presents policy challenges. This policy report examines the difference between public and private cord blood banks and offers recommendations for US policymakers to improve cord blood banking and ensure high quality standards.
Monica M. Matsumoto, Kirstin R.W. MatthewsOctober 6, 2014
In March 2009, the James A. Baker III Institute for Public Policy and the Qatar Foundation for Education, Science and Community Development co-hosted a workshop in Doha, Qatar, on stem cell research, policies, and regulations. The event highlighted current stem cell science, as well as stem cell policies and ethics. The discussion focused on policies around the globe and the religious views of embryonic stem cell research from the Christian, Jewish, and Muslim perspectives. The workshop was organized so that outcomes from the event could be relevant to the development of Qatar"s up-and-coming stem cell research. Based on the presentation from the event, the advisory panel for the Baker Institute International Stem Cell Policy Program made a series of recommendations for the new stem cell initiative in Qatar, including the suggestion for outreach to the Qatari community.